Emgality and Injection site urticaria - a phase IV clinical study of FDA data

Summary:

Injection site urticaria is reported as a side effect among people who take Emgality (galcanezumab-gnlm), especially for people who are female, 30-39 old, have been taking the drug for 1 - 6 months also take Ubrelvy, and have Migraine.

The phase IV clinical study analyzes which people have Injection site urticaria when taking Emgality. It is created by eHealthMe based on reports of 24,623 people who have side effects when taking Emgality from the FDA, and is updated regularly.

What is Emgality?

Emgality has active ingredients of galcanezumab-gnlm. eHealthMe is studying from 24,702 Emgality users. Check the latest studies of Emgality.

What is Injection site urticaria?

Injection site urticaria (rash of round, red welts on the skin at injection site) is found to be associated with 557 drugs and 612 conditions by eHealthMe. Check the latest studies of Injection site urticaria.

On Jul, 12, 2026

24,623 people reported to have side effects when taking Emgality.
Among them, 435 people (1.77%) have Injection site urticaria.

Could Emgality cause Injection site urticaria?

Among these 435 people:

How long have people been on Emgality when they have Injection site urticaria? *

Click here to view more results

What is the gender of people who have Injection site urticaria when taking Emgality? *

Click here to view

What is the age of people who have Injection site urticaria when taking Emgality? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Emgality and have Injection site urticaria?

- Check whether Injection site urticaria is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Emgality:

Emgality (24,702 reports)

Injection site urticaria treatments and more:

Injection site urticaria (21,717 reports)

How severe was Injection site urticaria and when was it recovered:

Injection site urticaria in Emgality

Expand to all the drugs that have ingredients of galcanezumab-gnlm:

Injection site urticaria and drugs with ingredients of galcanezumab-gnlm

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Emgality:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Injection site urticaria:

Injection site urticaria (557 drugs)

Browse all the conditions that are associated with Injection site urticaria:

Injection site urticaria (612 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on galcanezumab-gnlm (the active ingredients of Emgality) and Emgality (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.